|Consequences of polyparasitism on anaemia among primary school children in Zimbabwe|
N Midzi, S Mtapuri-Zinyowera, MP Mapingure, D Sangweme, ...
Acta tropica 115 (1-2), 103-111, 2010
|Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial.|
MR Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P ...
Open Forum Infectious Diseases 1 (1), ofu038, 2014
|Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction|
MT Chirehwa, R Rustomjee, T Mthiyane, P Onyebujoh, P Smith, ...
Antimicrobial agents and chemotherapy 60 (1), 487-494, 2015
|Use of the ‘accountability for reasonableness’ approach to improve fairness in accessing dialysis in a middle-income country|
MR Moosa, JD Maree, MT Chirehwa, SR Benatar
PLoS One 11 (10), e0164201, 2016
|Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB|
A Naidoo, M Chirehwa, H McIlleron, K Naidoo, S Essack, N Yende-Zuma, ...
Journal of Antimicrobial Chemotherapy 72 (5), 1441-1449, 2017
|Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and-resistant tuberculosis|
MT Chirehwa, H McIlleron, R Rustomjee, T Mthiyane, P Onyebujoh, ...
Antimicrobial agents and chemotherapy 61 (8), e00490-17, 2017
|CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz|
R Griesel, G Maartens, M Chirehwa, S Sokhela, G Akpomiemie, ...
Clin Infect Dis 70, 670-678, 2020
|Current research toward optimizing dosing of first-line antituberculosis treatment|
H McIlleron, MT Chirehwa
Expert review of anti-infective therapy 17 (1), 27-38, 2019
|HIV-1 coinfection does not reduce exposure to rifampin, isoniazid, and pyrazinamide in South African tuberculosis outpatients|
N Rockwood, G Meintjes, M Chirehwa, L Wiesner, H McIlleron, ...
Antimicrobial agents and chemotherapy 60 (10), 6050-6059, 2016
|Renal abnormalities among HIV-infected, antiretroviral naive children, Harare, Zimbabwe: a cross-sectional study|
V Dondo, HA Mujuru, KJ Nathoo, M Chirehwa, Z Mufandaedza
BMC pediatrics 13 (1), 1-9, 2013
|Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis|
A Naidoo, M Chirehwa, V Ramsuran, H McIlleron, K Naidoo, ...
Pharmacogenomics 20 (04), 225-240, 2019
|Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid|
MT Chirehwa, H McIlleron, L Wiesner, D Affolabi, O Bah-Sow, C Merle, ...
Journal of Antimicrobial Chemotherapy 74 (1), 139-148, 2019
|Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications|
MT Chirehwa, L Wiesner, B Wright, W Smythe, N Kramer, H McIlleron
The International Journal of Tuberculosis and Lung Disease 22 (5), 537-543, 2018
|Evaluation of the effectiveness of dose individualization to achieve therapeutic vancomycin concentrations|
AA Abulfathi, M Chirehwa, B Rosenkranz, EH Decloedt
The Journal of Clinical Pharmacology 58 (9), 1134-1139, 2018
|Propagation of measurement errors in glomerular filtration rate determination: a comparison of slope–intercept, single-sample and slope-only methods|
JL Holness, JS Fleming, MT Chirehwa, JM Warwick
Nuclear medicine communications 40 (4), 333-342, 2019
|Assessment of quality of obstetric care in Zimbabwe using the standard primipara|
BT Guzha, TL Magwali, B Mateveke, M Chirehwa, G Nyandoro, ...
BMC pregnancy and childbirth 18 (1), 1-6, 2018
|Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis|
A Naidoo, V Ramsuran, M Chirehwa, P Denti, H McIlleron, K Naidoo, ...
Pharmacogenomics 19 (1), 17-29, 2018
|Elective reconstruction of the ascending aorta for aneurysmal disease restores normal life expectancy. An analysis of risk factors for early and late mortality|
D Van Duffel, R Van Gemert, P Starinieri, JL Pauwels, A Natukunda, ...
Acta cardiologica 68 (4), 349-353, 2013
|Low antituberculosis drug concentrations in HIV-tuberculosis-coinfected adults with low body weight: Is it time to update dosing guidelines?|
C Sekaggya-Wiltshire, M Chirehwa, J Musaazi, A von Braun, A Buzibye, ...
Antimicrobial agents and chemotherapy 63 (6), e02174-18, 2019
|Population pharmacokinetics of cycloserine and pharmacokinetic/pharmacodynamic target attainment in multidrug-resistant tuberculosis patients dosed with terizidone|
MT Chirehwa, R Court, M de Kock, L Wiesner, N de Vries, J Harding, ...
Antimicrobial agents and chemotherapy 64 (11), e01381-20, 2020